KNSA
USDKiniksa Pharmaceuticals International plc Class A Ordinary Shares
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$39.080
Máximo
$39.220
Mínimo
$38.570
Volumen
0.35M
Fundamentos de la Empresa
Capitalización de Mercado
2.9B
Industria
Drug Manufacturers - Specialty & Generic
País
United Kingdom
Estadísticas de Negociación
Volumen Promedio
0.46M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals with a Buy and raises the price target from $45 to $55.
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals with a Outperform and raises the price target from $38 to $44.
Acciones Relacionadas
W
Wayfair Inc.
WHR
Whirlpool Corporation
AGNCL
AGNC Investment Corp. Depositary Shares Each Representing a 1/1000th Interest in a Share of 7.75% Series G Fixed-Rate Reset Cumulative Redeemable Preferred Stock
BGT
BlackRock Floating Rate Income Trust
HEQ
John Hancock Hedged Equity & Income Fund Common Shares of Beneficial Interest
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.